Generic Name and Formulations:
Erythromycin (as base) 250mg, 333mg, 500mg; e-c tabs.
Arbor Pharmaceuticals, LLC
- No Additional Benefits With Vaginal Estradiol Tablets, Moisturizers for Postmenopausal Vulvovaginal Symptoms
- Metabolic Syndrome Frequency Assessed in Systemic Lupus Erythematosus
- Bydureon Single Dose Trays to Be Discontinued
Indications for ERY-TAB:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
250mg every 6 hours, 500mg every 12 hours, or 333mg every 8 hours; max 4g/day; twice daily dosing max 1g/day. Legionnaires: 1–4g/day in divided doses.
30–50mg/kg/day in divided doses; max 100mg/kg/day.
Concomitant cisapride, pimozide.
Hepatic dysfunction. Myasthenia gravis. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP450 (eg, carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, disopyramide, bromocriptine, valproate). May potentiate warfarin, triazolam, midazolam, methylprednisolone, digoxin, theophylline, ergotamine. Avoid use with statins (rhabdomyolysis).
GI upset, abdominal pain, anorexia, hepatic dysfunction, rash, superinfection; pseudomembranous colitis, (rare).
250mg—30, 40, 100, 500; 333mg—30, 100, 500; 500mg—100
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency